Bacteroides fragilis: Difference between revisions
imported>Robert Badgett mNo edit summary |
imported>Howard C. Berkowitz No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 1: | Line 1: | ||
In [[microbiology]], '''''Bacteroides fragilis''''' is a "gram-negative bacteria occurring in the lower intestinal tracts of man and other animals. It is the most common species of anaerobic bacteria isolated from human soft tissue infections."<ref>{{MeSH}}</ref> | {{subpages}} | ||
{{TOC|right}} | |||
B frag may cause [[bacteremia]] | In [[microbiology]], '''''Bacteroides fragilis''''' is a "gram-negative bacteria occurring in the lower intestinal tracts of man and other animals. It is the most common species of anaerobic bacteria isolated from human soft tissue infections."<ref>{{MeSH}}</ref> They are variously described as part of the '''anaerobic gram negative bacilli''' (AGNB) or ''Bacteroidaceae'' family. While ''B. fragilis'' is most common clinically, other closely related pathogens include includes ''B. distasonis, B. ovatus, B.s thetaiotaomicron'', and ''Ba. vulgatus.''<ref name=eMed-BF-Over>{{citation | ||
| publisher = eMedicine | |||
| url = http://emedicine.medscape.com/article/233339-overview | |||
| title = Bacteroides Infection | |||
| author = Brook I | |||
| date = 29 October 2009}}</ref> | |||
==Distribution== | |||
''Bacteroides'' commonly present on mucous membranes, becoming part of infections after the tissue is damaged. Such infections often involve multiple aerobic and anaerobic species. Specialized culture techniques, however, are needed to confirm ''Bacteroides'' and they may be ignored. <ref name=Brook>{{citation | |||
| title = Treatment of anaerobic infection (abstract) | |||
| journal = Expert Rev Anti Infect Ther | |||
| year = 2007 | |||
| volume = 5 | issue = 6 | pages = 991-1006 | |||
| url = http://www.medscape.com/medline/abstract/18039083 | |||
| author = Brook I | |||
}}</ref> | |||
==Clinical manifestations== | |||
B frag may cause [[bacteremia]] <ref name="pmid7548498">{{cite journal| author=Redondo MC, Arbo MD, Grindlinger J, Snydman DR| title=Attributable mortality of bacteremia associated with the Bacteroides fragilis group. | journal=Clin Infect Dis | year= 1995 | volume= 20 | issue= 6 | pages= 1492-6 | pmid=7548498 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=7548498 }} </ref><ref name="pmid16341345">{{cite journal| author=Hung MN, Chen SY, Wang JL, Chang SC, Hsueh PR, Liao CH et al.| title=Community-acquired anaerobic bacteremia in adults: one-year experience in a medical center. | journal=J Microbiol Immunol Infect | year= 2005 | volume= 38 | issue= 6 | pages= 436-43 | pmid=16341345 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=16341345 }} </ref><ref name="pmid19812858">{{cite journal| author=Cheng CW, Lin HS, Ye JJ, Yang CC, Chiang PC, Wu TS et al.| title=Clinical significance of and outcomes for Bacteroides fragilis bacteremia. | journal=J Microbiol Immunol Infect | year= 2009 | volume= 42 | issue= 3 | pages= 243-50 | pmid=19812858 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=19812858 }} </ref> and [[soft tissue]] infections. | |||
==Treatment== | |||
Certainly in soft tissue infection, and where a source for bacteremia can be found, surgical drainage is important. Both due to the varying sensitivities of ''Bacteroides'', and the likelihood of mixed-flora infections, therapy with multiple antibiotics is usually desirable. Pending the availability of specific culture and sensitivity, reasonable approaches for the anaerobes alone include:<ref name=Brook/> | |||
*[[metronidazole]] | |||
*[[carbapenem]]s ([[imipenem]], [[meropenem]] and [[ertapenem]]) | |||
*[[chloramphenicol]] | |||
*combinations of a penicillin and a beta-lactamase inhibitor (ampicillin or ticarcillin plus clavulanate, amoxicillin plus sulbactam, and piperacillin plus tazobactam) | |||
*[[tigecycline]] | |||
*[[clindamycin]] | |||
==References== | ==References== | ||
<references/> | <references/> |
Latest revision as of 11:43, 13 June 2010
In microbiology, Bacteroides fragilis is a "gram-negative bacteria occurring in the lower intestinal tracts of man and other animals. It is the most common species of anaerobic bacteria isolated from human soft tissue infections."[1] They are variously described as part of the anaerobic gram negative bacilli (AGNB) or Bacteroidaceae family. While B. fragilis is most common clinically, other closely related pathogens include includes B. distasonis, B. ovatus, B.s thetaiotaomicron, and Ba. vulgatus.[2]
Distribution
Bacteroides commonly present on mucous membranes, becoming part of infections after the tissue is damaged. Such infections often involve multiple aerobic and anaerobic species. Specialized culture techniques, however, are needed to confirm Bacteroides and they may be ignored. [3]
Clinical manifestations
B frag may cause bacteremia [4][5][6] and soft tissue infections.
Treatment
Certainly in soft tissue infection, and where a source for bacteremia can be found, surgical drainage is important. Both due to the varying sensitivities of Bacteroides, and the likelihood of mixed-flora infections, therapy with multiple antibiotics is usually desirable. Pending the availability of specific culture and sensitivity, reasonable approaches for the anaerobes alone include:[3]
- metronidazole
- carbapenems (imipenem, meropenem and ertapenem)
- chloramphenicol
- combinations of a penicillin and a beta-lactamase inhibitor (ampicillin or ticarcillin plus clavulanate, amoxicillin plus sulbactam, and piperacillin plus tazobactam)
- tigecycline
- clindamycin
References
- ↑ Anonymous (2024), Bacteroides fragilis (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Brook I (29 October 2009), Bacteroides Infection, eMedicine
- ↑ 3.0 3.1 Brook I (2007), "Treatment of anaerobic infection (abstract)", Expert Rev Anti Infect Ther 5 (6): 991-1006
- ↑ Redondo MC, Arbo MD, Grindlinger J, Snydman DR (1995). "Attributable mortality of bacteremia associated with the Bacteroides fragilis group.". Clin Infect Dis 20 (6): 1492-6. PMID 7548498.
- ↑ Hung MN, Chen SY, Wang JL, Chang SC, Hsueh PR, Liao CH et al. (2005). "Community-acquired anaerobic bacteremia in adults: one-year experience in a medical center.". J Microbiol Immunol Infect 38 (6): 436-43. PMID 16341345.
- ↑ Cheng CW, Lin HS, Ye JJ, Yang CC, Chiang PC, Wu TS et al. (2009). "Clinical significance of and outcomes for Bacteroides fragilis bacteremia.". J Microbiol Immunol Infect 42 (3): 243-50. PMID 19812858.